Page 1222 - Basic _ Clinical Pharmacology ( PDFDrive )

1208 Index

Drugs of abuse (Cont.): cholesterol 7α-hydroxylase, 631 malathion, 1076
case study of, 575, 589 cholesteryl ester storage disease, 629t, permethrin, 1075
classes of, 577t 631 spinosad, 1075
clinical pharmacology of, 587–588 familial combined sulfur, 1075
G io protein-coupled receptors, drugs hyperlipoproteinemia, 629t, 631 Eculizumab, 995
activating, 581–583, 583f familial hypercholesterolemia, 629t, Edema
cannabinoids, 577t, 581–582, 583f 630, 631f estrogens on, 725
gamma-hydroxybutyric acid, 577t, familial ligand-defective apolipoprotein histamine-induced, 280
582, 583f B-100, 629t, 630 idiopathic, 270–271
LSD, mescaline, and psilocybin, 577t, HDL deficiency, 631f lithium as cause of, 527
582–583 Lp(a) hyperlipoproteinemia, 629t, 631 Edetate calcium disodium
opioids, 577t, 581, 583f PCSK9 mutations, 631 (ethylenediamine-tetraacetic acid,
ionotropic receptors, drugs mediating hyperlipidemia drugs, 632–638, 640t. EDTA), 1023, 1029f, 1031
effects via, 583–585 See also Hyperlipidemia drugs Edoxaban, 616–617
alcohol, 585 hyperlipoproteinemias, 627–632, 629t Edrophonium, 117, 122t
benzodiazepines, 584 dietary management, 632 myasthenia gravis treated with, 119
inhalants, 585 pathophysiology of, 627–631 neuromuscular blockade reversal using,
ketamine and phencyclidine, 585 hypertriglyceridemias, primary, 629t, 484
nicotine, 583–584 629–630 structure of, 115, 116f
neurobiology of, 575–581 lipid guidelines, 628, 629t Efavirenz, 871t, 877–878
addiction in lipoproteins in, 626 Effective dose, median (ED 50 ), 37, 37f
dopamine hypothesis of, 579b Dysmenorrhea, 726 Efficacy
as maladaptive learning, 578–580 Dysmorphogenesis, 523, 527 intrinsic, 5
animal models of, 578b Dyspepsia, nonulcer maximal, 36, 36f
dependence vs. addiction in, 575 H 2 -receptor antagonists for, 1091 practical, 36
dopamine reinforcement in, 575–576 metoclopramide and domperidone for, Effort angina, 194
nonaddictive, 577t, 580 1097 Efinaconazole, 1072
tolerance, 576–578 proton-pump inhibitors for, 1094 Eflornithine
withdrawal, 576–578 Dystonia, 492, 505 topical, 1085
nonaddictive, 577t, 580 acute, from antipsychotics, 522 trypanosomiasis and leishmaniasis
d-Tubocurarine, 475, 478t tardive, 505 treated with, 934
Ductus arteriosus delayed closure, COX Eicosanoid receptors, 326–327, 327f, 328t
inhibitors for, 335 E Eicosanoids, 321–338
Dulaglutide, 762, 769t Early afterdepolarizations (EADs), 233, 233f arachidonic acid and other polyunsatu-
Duloxetine, 151, 537, 540, 540t, 546t, Ecallantide, 308, 317t. See also Kinin rated precursors, 321–322, 322f
550t. See also Serotonin- inhibitors case study of, 321, 338
norepinephrine reuptake Ecamsule, in sunscreen, 1076 clinical pharmacology of, 333–337
inhibitors (SNRIs Echinacea (Echinacea purpurea), blood, 335–336
Dupilumab, 357, 363t 1134–1136 cardiovascular system, 335–336
Duration Echinocandins, 853 gastrointestinal system, 336
of drug action, 6–7 caspofungin, 859, 861t immune system, 336–337
of exposure, 1005 preparations available, 862t renal system, 335
Dutasteride, 744, 745t Echinococcus reproductive system
Dyazide, 266t albendazole for, 939t, 940 female, 334–335
Dynorphins, 554, 554t praziquantel for, 944–945 male, 335
Dyrenium, 266t Echothiophate, 115–116, 116f, 122t. respiratory system, 336
Dysbetalipoproteinemia, familial, 629t, 630 See also Organophosphate structures of, 333f
Dyskinesias cholinesterase inhibitors dietary manipulation of metabolism of,
drug-induced, 506 Econazole, 1072 337
from levodopa, 497 Ecotoxicology, 1005 mechanisms and effects of, 326–332
tardive, 506 Ecstasy (MDMA) in lipoxygenase and cytochrome P450-
antipsychotics as cause of, 522 acamprosate for dependence on, 589t derived metabolites, 331–332
Dyslipidemia, 626–641 description of, 577t, 587 prostaglandins and thromboxanes,
atherogenesis from, 627 Ectoparasiticides 327–331
hypercholesterolemias, primary benzyl alcohol, 1076 receptor mechanisms in, 326–327,
ABCG5 and ABCG8 mutations, 631 crotamiton, 1075 327f, 328t
autosomal recessive ivermectin, 1075 NSAIDs on synthesis of, 332
hypercholesterolemia, 631 lindane, 1075 preparations available, 337t